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ABSTRACT Skin cancers are the most common malignancies in renal transplant 
recipients, with squamous-cell and basal-cell cancers accounting for the major-
ity of all skin cancer cases. Melanoma is relatively rare in this group of patients. 
From 1973 to May 2017, out of 1889 patients who received allografts at our in-
stitution, 4 developed melanoma. After the mean follow-up of 11.5 months, 2 
patients died and 2 are still alive with functioning allografts. Malignancies were 
localized in the legs in both female patients, and in the neck and head in 1 male 
patient each. Compared to the general population of Croatia, renal transplant 
recipients from our cohort have 6.85 times higher risk for development of mela-
noma. Regular screenings and patient education are mandatory, especially in 
Mediterranean countries.
KEY WORDS: skin cancer, melanoma, renal transplantation, immunosuppres-
sion, outcome
INTRODUCTION
Skin cancers are the most common malignancies 
in renal transplant recipients. Squamous-cell and bas-
al-cell cancers account for the majority of all skin can-
cer cases and are clearly associated with prolonged 
exposure to immunosuppression (1,2). Melanoma is 
relatively rare in this group of patients, but the risk is 
still 2 to 3 times higher when compared with the gen-
eral population. Literature on melanoma in the renal 
transplant population is scarce.
Herein we report clinical characteristics of patients 
who developed melanoma after renal transplantation 
at our institution.
PATIENTS AND METHODS
This retrospective study included all renal trans-
plant recipients who received a renal allograft at the 
University Hospital Centre Zagreb and developed 
post-transplant melanoma from 1973 to May 2017. 
Patients were followed by nephrologists and derma-
tologists. Data were retrieved from the database of 
the Department of Nephrology, Arterial Hyperten-
sion, Dialysis and Transplantation, University Hospital 
Centre Zagreb and from medical charts and records.
The data collection included patient age and gen-
der; dialysis vintage; immunosuppressive regimen 
before and after diagnosis of malignancy (induction 
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with basiliximab or antythymocyte globuline (ATG), 
maintenance with either azathioprine, prednisone, 
cyclosporine, everolimus, mycophenolate mofetil, or 
tacrolimus); rejection episodes; time from transplan-
tation until the diagnosis of malignancy; other con-
current neoplastic problems; time of follow-up and 
outcome.
Before the year 2000, patients received triple 
maintenance immunosuppression with cyclosporine, 
prednisone, and azathioprine. After 2000, the major-
ity of patients were taking cyclosporine, prednisone, 
and MMF, and tacrolimus instead of cyclosporine from 
2009. Simulect was used for induction in all patients 
from 2007, and ATG in cases of second transplanta-
tion or in sensitized patients.
RESULTS
Four patients out of the 1889 renal transplant 
recipients developed melanoma over the observed 
period, resulting in a prevalence of 0.2%. There were 
2 male and 2 female patients. Mean dialysis vintage 
was 3.25 years. One patient was treated with perito-
neal dialysis, and 3 with hemodialysis. Mean age at 
transplantation was 57 years. Two patients received 
basiliximab induction followed by tacrolimus, myco-
phenolate, and steroid maintenance, 1 was treated 
with cyclosporine, mycophenolate and steroids, and 
1 with cyclosporine, azathioprine, and steroids. Mean 
age at diagnosis of malignancy was 64.75 years (range 
61-69) with median exposure to immunosuppression 
of 7.625 years (range 1.5-20.0). Melanomas were lo-
calized at the legs in 2 female patients and at the neck 
and the head in 1 patient each. All patients underwent 
surgical excision. Tacrolimus was switched to everoli-
mus in 2 patients, while in 1 patient cyclosporine was 
omitted from the immunosuppressive protocol (she 
was diagnosed before the introduction of mTOR in-
hibitors in Croatia). A male patient (Number 3) had 
proteinuria, which was a contraindication for a switch 
from cyclosporine to everolimus. Thus, cyclosporine 
was discontinued and treatment continued with my-
cophenolate and steroids (Table 1).
Median follow-up after diagnosis of melanoma 
was 11.5 months. Two patients died, and 2 are still 
alive with functioning allografts.
DISCUSSION
There is conflicting data on the incidence of mela-
nomas in renal transplant recipients. Some epidemio-
logic studies have shown that the risk of melanoma 
is increased after renal transplantation (3), however, 
a study from the Netherlands did not find increased 
risk for development of melanoma in this group of 
patients (4). The pathogenesis of these neoplasms 
is likely related to immune suppression after organ 
transplantation and subsequent viral infection (2,5). 
Lindelof et al. evaluated 5356 patients over a 24-year 
period, with melanoma found in 6 patients. The au-
thors concluded that transplant patients had no in-
creased risk for development of melanoma (6). The 
United States Renal Data System (USRDS) found a 
2.2-fold increase in melanoma among renal trans-
plant recipients (1). Later, Hollenbeak et al. also using 
data from USRDS (7), found 246 cases of melanoma 
among 89786 renal transplant recipients from 1988 
and 1998. The age-adjusted incidence rate of mela-
noma was 55.9 cases per 100000 individuals, which 
is a 3.6 times greater age-adjusted standardized risk 
compared with the general population. The Penn 
Israel registry recorded 177 de novo patients with 
melanoma in their transplant population over a 27-
year-period (8). Melanoma (mostly Breslow thickness 
>0.76 mm) was more common in men, occurred 1 to 
244 months after transplantation, most on the trunk, 
upper limbs, head, and neck. According to data pub-
lished in the Croatian National Cancer Registry for 
year 2014 (9), incidence of melanoma was 0.137 per 
1000 citizens, which is 6.85 times lower than in our 
renal transplant population.
The outcomes of patients who develop mela-
noma after renal transplantation depends primarily 
on the characteristics of the malignancy. It appears 
that those patients with melanoma Breslow thickness 
<0.76 mm have a good prognosis, as in the general 



















1 F 4 61 5.0 Bas, tac, MMF, ster everolimus 66 0.35 leg 22 No Alive
2 M 5 59 1.5 CyA, MMF, ster 61 4.00 head 6 Meta Exitus 
3 M 2 65 4.0 Bas, tac, MMF, ster everolimus 69 1.40 neck 7 No Alive
4 F 2 43 20.0 CyA, Aza, ster 63 5.00 leg 11 Meta Exitus 
F: female; M: male; tx: transplantation; Bas: basiliximab; tac: tacrolimus, cyA: cyclosporine A; MMF: mycophenolate mofetil;  
Aza: azathioprine; ster: steroids; Meta: metastasis; yr: year; mo: month
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population, while patients with Breslow thickness 
>0.76 mm may have increased mortality (8,10-13). 
Harwood et al. reported outcomes in 7 patients, 2 
with in situ melanoma and 5 with invasive melanoma 
(14). Three patients died from metastatic disease; 2 
of them with Breslow >2 mm. However, one patient 
developed metastases from a lentigo maligna mela-
noma with Breslow thickness of 0.4 mm. In a report 
by Dapprich et al. who followed 31 patients with de 
novo malignant melanoma after transplantation with 
Breslow thicknesses ranging from in situ to 6.1 mm 
(median, 0.75 mm), Breslow depths greater than 1.0 
mm were associated with recurrences, metastasis, 
and death (15). Among 139991 non-Hispanic white 
transplants recorded in the US transplant-cancer reg-
istry data (1987-2010), the risk of invasive melanoma 
(n=519) was elevated 2.2 times. Risk of localized tu-
mors was higher with azathioprine maintenance 
therapy. Risk of regional/distant stage tumors was 
the highest 4 years following transplantation and in-
creased with the use of polyclonal antibodies. Mortal-
ity from melanoma was higher among transplant re-
cipients than in the general population (hazard ratio 
2.98) (16). 
It is interesting that 2 of our patients (50%) had 
other malignancies associated with melanoma (pap-
illary thyroid carcinoma and renal adenocarcinoma; 
submandibular gland tm). Bae et al. analyzed other 
primary cancers in 452 patients with melanoma from 
1994 to 2013. They found 51 cases (11.2%) of other 
primary cancers, most commonly gastrointestinal, 
thyroid, lung, and breast cancer (17).
Immunosuppression is an important factor in de-
velopment of post-transplant malignancies. mTOR 
inhibitors were found to decrease the incidence of 
malignancies in renal transplant recipients (18). Ex-
perimental models on mice demonstrated that treat-
ment with mTOR inhibitors inhibited melanoma tu-
mor growth (19). These results may support a switch 
from calcineurin-inhibitor-based- to mTOR-inhibi-
tor-based immunosuppression after development of 
melanoma.
Prevention should be the primary approach in 
the renal transplant population. Patients should be 
instructed on self-examination of the skin and sun 
protection strategies. Dermatologic examinations 
should be performed on all patients at high risk, with 
special attention to all pigmented lesions and exci-
sional biopsies performed on all suspicious nevi. 
 
CONCLUSION
Melanoma is relatively rare in the renal transplant 
population; however, it was found to be 6.85x more 
common in this group when compared with the gen-
eral population.
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